Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apratastat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 known ✓ | P78536 | 19/20 | 1.00 |
| ▸ | MMP13 known ✓ | P45452 | 19/20 | 1.00 |
| ▸ | MMP1 | P03956 | 20/20 | 1.00 |
| ▸ | MMP9 | P14780 | 4/20 | 1.00 |
| ▸ | MMP3 | P08254 | 3/20 | 1.00 |
| ▸ | ADAM10 | O14672 | 2/20 | 1.00 |
| ▸ | ADAM9 | Q13443 | 2/20 | 1.00 |
| ▸ | MMP2 | P08253 | 2/20 | 0.84 |
| ▸ | MMP7 | P09237 | 1/20 | 0.71 |
| ▸ | MMP8 | P22894 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apratastat SCHEMBL2834310 | 1.00 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9MMP3 | |
| Apratastat SCHEMBL7430863 | 0.99 | MMP1 (0.98) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL3941060 | 0.95 | MMP1 (0.90) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL3944800 | 0.93 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL12272230 | 0.93 | MMP1 (0.86) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL7325140 | 0.93 | MMP1 (0.86) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL7325752 | 0.93 | MMP1 (0.86) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL3941871 | 0.93 | MMP1 (0.86) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL3945436 | 0.92 | MMP1 (1.00) | MMP1ADAM17MMP13MMP9MMP3 | |
| SCHEMBL3948013 | 0.92 | MMP1 (0.85) | MMP1ADAM17MMP13MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180000817-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2018-01-04 | — | — | US | claimed |
| EP-3244883-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2017-11-22 | — | — | EP | claimed |
| WO-2016113713-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2016-07-21 | — | — | WO | claimed |
| WO-2005123706-A9 | CRYSTALLINE POLYMORPHS OF (3S)-N-HYDROXY-4({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE | WYETH CORP (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2005123706-A1 | CRYSTALLINE POLYMORPHS OF (3S)-N-HYDROXY-4({4-[(4-HYDROXY-2-BUTYNYL)OXY]PHENYL}SULFONYL)-2,2-DIMETHYL-3-THIOMORPHOLINE CARBOXAMIDE | WYETH (US) | 2005-12-29 | — | — | WO | claimed |
| EP-1144368-B1 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-14 | — | — | EP | claimed |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | claimed |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2003-11-13 | — | — | US | claimed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | claimed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | claimed |
| EP-3860608-A1 | EGFR INHIBITORS FOR TREATING KERATODERMAS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020070239-A1 | EGFR INHIBITORS FOR TREATING KERATODERMAS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-04-09 | — | — | WO | disclosed |
| US-20180000817-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2018-01-04 | — | — | US | disclosed |
| EP-3244883-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016113713-A1 | TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME AND DISEASES RELATED TO VASCULAR AGEING | Biocant - Associação De Transferência De Tecnologia (PT) | 2016-07-21 | — | — | WO | disclosed |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | disclosed |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2003-11-13 | — | — | US | disclosed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | disclosed |
| WO-2002083112-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH HOLDINGS CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | ADAM17 29/4885MMP13 114/4885MMP1 130/4885 |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | ADAM17 29/4885MMP13 114/4885MMP1 130/4885 |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | ADAM17 29/4885MMP13 114/4885MMP1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.